NervGen Pharma Provides Update on Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury
Target enrollment in the chronic cohort close to completion Vancouver, Canada, September 30, 2024 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced that target enrollment of the chronic cohort in its Phase 1b/2a proof-of-concept, double-blind, randomized […]
NervGen Pharma to Present at the Unite 2 Fight Paralysis 19th Annual Science & Advocacy Symposium Focused on Spinal Cord Injury
Vancouver, Canada, September 20, 2024 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Daniel Mikol, MD, Ph.D., NervGen’s Chief Medical Officer, will give an oral presentation at the Unite 2 Fight Paralysis (U2FP) 19th Annual Science […]
NervGen Pharma to Present at the 63rd International Spinal Cord Society Annual Scientific Meeting
Vancouver, Canada, September 16, 2024 — NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Daniel Mikol, MD, Ph.D., NervGen’s Chief Medical Officer, will present at the 63rd International Spinal Cord Society (ISCoS) Annual Scientific Meeting, taking place […]
NervGen Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Vancouver, Canada, August 27, 2024 — NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Mr. Mike Kelly, President & CEO, will be presenting at the H.C. Wainwright 26th Annual Global Investment Conference, on Tuesday, September 10, 2024, at […]
NervGen Pharma Reports Q2 2024 Financial Results and Operational Updates
Targeting to complete enrollment in the Phase 1b/2a chronic cohort in Q3 2024 Protocol being amended to enhance enrollment and lessen burden on participants in the subacute cohort NVG-300 advanced into preclinical proof-of-concept studies in ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI) Vancouver, Canada, August 22, 2024 – NervGen Pharma […]
NervGen Pharma to Present at the Canaccord Genuity 44th Annual Growth Conference
Vancouver, Canada, August 6, 2024 — NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Mr. Mike Kelly, President & CEO, will be presenting at the Canaccord Genuity 44th Annual Growth Conference, on August 13, 2024, at 10:00 a.m. […]
NervGen Pharma Grants Stock Options
Vancouver, Canada. August 2, 2024 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQB: NGENF) a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the company has granted 30,000 incentive stock options to employees of the company and 15,000 incentive stock options to existing consultants providing investor […]
NervGen Pharma Appoints Neil Klompas to Board of Directors
Seasoned pharmaceutical executive with extensive experience in high-growth life sciences companies joins NervGen Leadership appointment supports the company’s mission to advance NVG-291 after the completion of the ongoing Phase 1b/2a study Vancouver, Canada, July 22, 2024 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the […]
NervGen Pharma to Advance NVG-300 into Preclinical Proof-of-Concept Stage
New molecule demonstrates efficacy in a challenging SCI model Expanding pipeline into new indications of ischemic stroke and ALS Vancouver, Canada June 25, 2024 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced its plans for the […]
NervGen Pharma to Present at the 2nd Annual Spinal Cord Injury Investor Symposium
Vancouver, Canada, June 20, 2024 — NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Mr. Mike Kelly, President & CEO, will be presenting a corporate update at the 2nd Annual Spinal Cord Injury Investor Symposium (“2nd SCIIS”), presented […]